ABSTRACT
PURPOSE: The objective of this phase III study was to determine the efficacy, safety, and pharmacokinetics of denileukin diftitox (DAB389IL-2, Ontak [Ligand Pharmaceuticals Inc, San Diego, CA]) in patients with stage Ib to IVa cutaneous T-cell lymphoma (CTCL) who have previously received other therapeutic interventions. PATIENTS AND METHODS: Patients with biopsy-proven CTCL that expressed CD25 on > or = 20% of lymphocytes were assigned to one of two dose levels (9 or 18 microg/kg/d) of denileukin diftitox administered 5 consecutive days every 3 weeks for up to 8 cycles. Patients were monitored for toxicity and clinical efficacy, the latter assessed by changes in disease burden and quality of life measurements. Antibody levels of antidenileukin diftitox and anti-interleukin-2 and serum concentrations of denileukin diftitox were also measured. RESULTS: Overall, 30% of the 71 patients with CTCL treated with denileukin diftitox had an objective response (20% partial response; 10% complete response). The response rate and duration of response based on the time of the first dose of study drug for all responders (median of 6.9 months with a range of 2.7 to more than 46.1 months) were not statistically different between the two doses. Adverse events consisted of flu-like symptoms (fever/chills, nausea/vomiting, and myalgias/arthralgias), acute infusion-related events (hypotension, dyspnea, chest pain, and back pain), and a vascular leak syndrome (hypotension, hypoalbuminemia, edema). In addition, 61% of the patients experienced transient elevations of hepatic transaminase levels with 17% grade 3 or 4. Hypoalbuminemia occurred in 79%, including 15% with grade 3 or 4 changes. Tolerability at 9 and 18 microg/kg/d was similar, and there was no evidence of cumulative toxicity. CONCLUSION: Denileukin diftitox has been shown to be a useful and important agent in the treatment of patients whose CTCL is persistent or recurrent despite other therapeutic interventions.
Subject(s)
Antineoplastic Agents/therapeutic use , Diphtheria Toxin , Interleukin-2 , Lymphoma, T-Cell, Cutaneous/drug therapy , Proteins/therapeutic use , Adult , Aged , Aged, 80 and over , Antineoplastic Agents/administration & dosage , Antineoplastic Agents/pharmacokinetics , Drug Administration Schedule , Female , Humans , Immunohistochemistry , Lymphoma, T-Cell, Cutaneous/metabolism , Lymphoma, T-Cell, Cutaneous/pathology , Male , Middle Aged , Neoplasm Staging , Proteins/administration & dosage , Proteins/pharmacokinetics , Receptors, Interleukin-2/metabolism , Recombinant Fusion Proteins , Remission InductionSubject(s)
Calcitriol/therapeutic use , Psoriasis/radiotherapy , Ultraviolet Therapy , Administration, Oral , Calcitriol/administration & dosage , Calcitriol/adverse effects , Calcium/blood , Calcium/urine , Combined Modality Therapy , Double-Blind Method , Humans , Hypercalcemia/etiology , Placebos , Psoriasis/drug therapy , Ultraviolet Therapy/adverse effectsABSTRACT
We describe a patient with chronic renal disease and secondary hyperparathyroidism who developed a lesion of granuloma annulare with evidence of calcium in the lesion. The lesion developed after an intravenous infusion of calcium gluconate.
Subject(s)
Arm , Calcinosis/complications , Granuloma Annulare/complications , Granuloma Annulare/pathology , Hyperparathyroidism, Secondary/complications , Kidney Failure, Chronic/complications , Adult , Biopsy, Needle , Diagnosis, Differential , Female , Granuloma Annulare/diagnosis , Humans , Hyperparathyroidism, Secondary/diagnosis , Kidney Failure, Chronic/diagnosis , Photomicrography , Remission, SpontaneousABSTRACT
Porphyria cutanea tarda-like blistering, fragility, and scarring of light-exposed skin was observed in four children with the Alagille syndrome. Abnormally elevated levels of serum porphyrins, of which coproporphyrin isomers I and III together accounted for 50%-89% of the total, were found in these four children but also in three other children with the Alagille syndrome without such skin lesions. The ratio for isomer I to III for total serum coproporphyrin concentration was determined in six cases; the concentration of isomer I was greater than or equal to that of isomer III in each case. Urinary total porphyrin excretion was found to be elevated in six of the seven cases, with 72% +/- 8% occurring as coproporphyrins I and III. The ratio for urinary coproporphyrin I to III was greater than or equal to 1 in six of these patients, the reverse of the typical normal isomer distribution. Inasmuch as the presence or absence of photocutaneous lesions did not correlate with levels of porphyrins in serum or urine, other factors may be involved in the pathogenesis of the skin lesions.
Subject(s)
Cholestasis, Intrahepatic/metabolism , Coproporphyrins/blood , Coproporphyrins/urine , Photosensitivity Disorders/metabolism , Porphyrins/blood , Porphyrins/urine , Adolescent , Adult , Child , Child, Preschool , Chronic Disease , Female , Humans , Isomerism , Male , SyndromeABSTRACT
Aleukemic leukemia cutis is a rare condition in which patients have skin lesions containing leukemic cells before evidence of leukemia can be detected in the peripheral blood. There are only 23 cases of this phenomenon documented in the English literature. We describe a 62-year-old woman who developed a diffuse, clinically benign-appearing cutaneous eruption, which histologically showed an atypical infiltrate of cells, 4 months before leukemic cells were found in her peripheral blood and the diagnosis of acute myelomonocytic leukemia was made by bone marrow aspiration. This case illustrates the difficulty in diagnosing leukemia cutis from examination of routine histologic sections and the importance of specialized marker studies in determining the cause of an atypical cellular infiltrate of the skin. It also illustrates how leukemia cutis can masquerade as a clinically benign-appearing cutaneous eruption in a seemingly healthy patient with normal blood parameters.
Subject(s)
Erythema/diagnosis , Leukemia, Myelomonocytic, Acute/diagnosis , Leukemia/diagnosis , Antineoplastic Agents/therapeutic use , Bone Marrow Examination , Erythema/drug therapy , Erythema/pathology , Female , Humans , Leukemia/drug therapy , Leukemia, Myelomonocytic, Acute/drug therapy , Middle AgedABSTRACT
We conducted a double-blind placebo-controlled clinical trial on 98 subjects to assess the efficacy of two strengths of topical human leukocyte alpha-interferon, 10(4) and 10(6) IU/g in a 1% nonoxynol-9 base, in the treatment of recurrent genital herpes simplex virus (HSV). The study medication was applied during the prodromal phase or at the first sign of recurrence of the infection. The high-dose alpha-interferon was found to be significantly more effective than the low-dose interferon and placebo with respect to the duration of viral shedding as well as in reducing the time to the end of all subjective symptoms, including pain, burning and itching. No difference between the three groups was found in times to crusting or healing. Further studies of topical interferon in the treatment of HSV and other viral infections are merited.
Subject(s)
Herpes Simplex/drug therapy , Interferon Type I/administration & dosage , Administration, Topical , Adolescent , Adult , Double-Blind Method , Drug Synergism , Female , Herpes Simplex/pathology , Humans , Interferon Type I/therapeutic use , Male , RecurrenceABSTRACT
Equilibrium constants for the binding of protoporphyrin to serum albumin and hemopexin and liver cytosolic fatty acid-binding protein of the rat were determined fluorometrically. The experimental equilibrium constant [10(6) M-1 (mean +/- S.D.)] values were 8.4 +/- 1.3, 10.0 +/- 2.4 and 34.0 +/- 3.0 for albumin, hemopexin and liver fatty acid-binding protein, respectively. Statistical analysis showed the equilibrium constant of binding of protoporphyrin to liver fatty acid-binding protein to be significantly (p less than 0.01) higher than that to albumin and hemopexin. The data suggest that in patients with erythropoietic protoporphyria an equilibrium gradient may exist which favors the uptake by hepatocytes of plasma protoporphyrin as a result of its greater affinity for intracellular liver fatty acid-binding protein.
Subject(s)
Carrier Proteins/metabolism , Hemopexin/metabolism , Liver/analysis , Neoplasm Proteins , Nerve Tissue Proteins , Porphyrins/metabolism , Protoporphyrins/metabolism , Serum Albumin/metabolism , Animals , Cytosol/analysis , Fatty Acid-Binding Protein 7 , Fatty Acid-Binding Proteins , Protein Binding , Rats , Spectrometry, FluorescenceABSTRACT
Digitate hyperkeratoses are rare lesions of unknown cause. We wish to add a new variant of this entity to the few reports in the literature. Our patient is a 79-year-old woman with palmar pits and digitate hyperkeratoses limited to her palms and soles.
Subject(s)
Keratoderma, Palmoplantar/pathology , Skin/pathology , Aged , Female , HumansABSTRACT
Incorrect diagnosis of photoallergy to sunscreen products represents a unique clinical dilemma. Increasing sunscreen usage for suspected idiopathic photosensitivity or a change to a sunscreen containing the same photoallergen only worsens the problem. While photoallergy to p-aminobenzoic acid and its esters is well known by dermatologists and the lay public, benzophenone photoallergy is not well appreciated. We report herein the cases of four individuals with photoallergy to oxybenzone in sunscreens. It is likely that such reactions will become more commonplace since oxybenzone is by far the most frequently used agent in modern, high sun protection factor sunscreens (greater than 8 sun protection factor) being marketed today.
Subject(s)
Benzophenones/adverse effects , Photosensitivity Disorders/chemically induced , Sunscreening Agents/adverse effects , 4-Aminobenzoic Acid/adverse effects , Aged , Female , Humans , Male , Middle Aged , Ultraviolet RaysABSTRACT
We report four patients with antibodies to human immunodeficiency virus and/or acquired immunodeficiency syndrome who were noted to have unique vascular lesions that clinically resembled Kaposi's sarcoma or pyogenic granulomas. The lesions were asymptomatic erythematous-violaceous papules and nodules. They erupted over several weeks, without predilection for a specific cutaneous site. Most lesions resolved spontaneously. Histologically these lesions revealed a proliferation of vascular spaces lined by plump, cuboidal endothelial cells embedded in an edematous stroma with an inflammatory infiltrate. It is unclear if these lesions represent Kaposi's sarcoma or pyogenic granulomas or if they are distinct neoplasms associated with human immunodeficiency virus.